Research
Next-generation KRAS G12C inhibitor improves survival in lung cancer
Nature ·
The Brief
- A next-generation KRAS G12C inhibitor is reported to improve survival in lung cancer.
- Only the headline was available; the source has no summary, so no trial details are known.
Why it matters
It reports a survival benefit from a targeted KRAS G12C drug, which is relevant to lung cancer treatment research.
Who’s affected
- oncologists and lung cancer researchers